drugset / Trial / NCT05305040

Study of Posoleucel (ALVR105,Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant

NCT05305040 ↗

Phase 2/3 Terminated 451 enrolled AlloVir
RandomizedParallel-groupQuadruple-blindPrevention

Summary

This is a Phase 3 study to evaluate posoleucel (ALVR105, Viralym-M); an allogeneic, off-the-shelf multi-virus specific T cell therapy that targets six viral pathogens: BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6 and JC virus.

Timeline

Start
2022-03-24
Primary completion
2024-01-30
Completion
2024-01-30

Outcome

Missed primary endpoint

Stopped: “Study discontinued as DSMB determined it was futile. No safety concerns were noted.”

registry analysis (superiority test); Posoleucel (ALVR105) vs Placebo; p = 0.5603; Mean Difference (Final Values) 0.01 (95% CI -0.09 to 0.10); ANCOVA; note: 1-sided p-value NCT05305040 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Posoleucel Cell therapy 2 ml Other
Subject Posoleucel Cell therapy 4 ml Other